LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3180 | 3772 | 0.8433 | 0.7632 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3280 | 3772 | 0.8700 | 0.8040 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3362 | 3772 | 0.8914 | 0.8363 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3603 | 3772 | 0.9554 | 0.9339 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3439 | 3772 | 0.9116 | 0.8674 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 72 | hr | 1476 | 2785 | 3772 | 0.7384 | 0.5979 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2980 | 3772 | 0.7903 | 0.6803 |
| SK-BR-3 | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 2925 | 3772 | 0.7758 | 0.6572 |
| SK-BR-3 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 2957 | 3772 | 0.7841 | 0.6709 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 2684 | 3772 | 0.7117 | 0.5554 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2297 | 3772 | 0.6090 | 0.3862 |
| SK-BR-3 | Momelotinib | 10 | uM | LJP5 | 72 | hr | 1476 | 1529 | 3772 | 0.4054 | 0.0261 |
| SK-BR-3 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 4159 | 3772 | 1.1030 | 1.1505 |
| SK-BR-3 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3803 | 3772 | 1.0083 | 1.0123 |
| SK-BR-3 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3521 | 3772 | 0.9338 | 0.9009 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3042 | 3772 | 0.8070 | 0.7062 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2275 | 3772 | 0.6034 | 0.3766 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 72 | hr | 1476 | 1177 | 3772 | 0.3120 | -0.1559 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2426 | 3772 | 0.6433 | 0.4435 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 2777 | 3772 | 0.7365 | 0.5953 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 2543 | 3772 | 0.6742 | 0.4943 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 2673 | 3772 | 0.7089 | 0.5509 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2661 | 3772 | 0.7056 | 0.5454 |
| SK-BR-3 | Trametinib | 10 | uM | LJP5 | 72 | hr | 1476 | 2560 | 3772 | 0.6789 | 0.5021 |
| SK-BR-3 | Omipalisib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1541 | 3643 | 0.4224 | 0.0293 |